A Machine Vision Perspective on Droplet-Based Microfluidics.

Microfluidic droplets, with their unique properties and broad applications, are essential in in chemical, biological, and materials synthesis research. Despite the flourishing studies on artificial intelligence-accelerated microfluidics, most research efforts have focused on the upstream design phase of microfluidic systems. Generating user-desired microfluidic droplets still remains laborious, inefficient, and time-consuming.

Three-dimensional printing-guided percutaneous transcatheter replacement in coarctation of the aorta: a retrospective study.

Background: To evaluate the feasibility, effectiveness and assistant effect of 3D printed aortic model in the treatment on congenital coarctation of the aorta (CoA) in adolescents and adults.

Methods: From December 2018 to December 2023, a total of 10 patients with congenital coarctation of aorta underwent percutaneous balloon dilatation covered stent implantation in the department of cardiovascular surgery, Xijing Hospital. There were 6 males and 4 females whose average age was (27.

Metabolic Engineering of for Efficient Production of Ectoine.

Ectoine is a valuable compatible solute with extensive applications in bioengineering, cosmetics, medicine, and the food industry. While certain halophilic bacteria can naturally produce ectoine, as a model organism for biomanufacturing, offers significant advantages to be engineered for potentially high-level ectoine production. However, complex metabolic flux distributions and byproduct formation present bottlenecks that limit ectoine production in .

The association between sodium-glucose cotransporter 2 inhibitors and contrast-associated acute kidney injury in patients with type 2 diabetes undergoing angiography: a propensity-matched study.

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been proven to prevent decline in kidney function and failure. Whether SGLT2i affect the risk of contrast-associated acute kidney injury (CA-AKI) remains uncertain.

Methods: Use of SGLT2i was assessed in consecutive diabetics undergoing coronary angiography (CA) or percutaneous coronary intervention (PCI) from January 2020 to May 2023 at a tertiary hospital in Chongqing, China.